Comparison 3. Tibolone versus combined HT.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Vasomotor symptoms	9	1336	Std. Mean Difference (Fixed, 95% CI)	0.17 [0.06, 0.28]
1.1 Tibolone, 2.5 mg/day	9	1336	Std. Mean Difference (Fixed, 95% CI)	0.17 [0.06, 0.28]
2 Unscheduled bleeding	16	6438	Odds Ratio (M‐H, Random, 95% CI)	0.32 [0.24, 0.41]
2.1 Tibolone, 2.5 mg/day	16	4720	Odds Ratio (M‐H, Random, 95% CI)	0.34 [0.26, 0.45]
2.2 Tibolone, 1.25 mg/day	2	1718	Odds Ratio (M‐H, Random, 95% CI)	0.21 [0.16, 0.26]
3 Endometrial cancer	5		Odds Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Tibolone, 2.5 mg/day	5	3689	Odds Ratio (M‐H, Random, 95% CI)	1.47 [0.23, 9.33]
4 Breast cancer; women without previous breast cancer	5		Odds Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 Tibolone (all doses)	5	4835	Odds Ratio (M‐H, Random, 95% CI)	1.69 [0.78, 3.67]
5 Venous thromboembolic events (clinical evaluation)	4		Odds Ratio (M‐H, Random, 95% CI)	Subtotals only
5.1 Tibolone (all doses)	4	4529	Odds Ratio (M‐H, Random, 95% CI)	0.44 [0.09, 2.14]
6 Cardiovascular events; all women's mean age below 60 years. No data available on different doses	2	3794	Odds Ratio (M‐H, Random, 95% CI)	0.63 [0.24, 1.66]
7 Cerebrovascular events; women's mean age below 60 years	4		Odds Ratio (M‐H, Random, 95% CI)	Subtotals only
7.1 Tibolone (all doses)	4	4562	Odds Ratio (M‐H, Random, 95% CI)	0.76 [0.16, 3.66]
8 Mortality from any cause	2		Odds Ratio (M‐H, Random, 95% CI)	Subtotals only
8.1 Tibolone, 2.5 mg/day	2	970	Odds Ratio (M‐H, Random, 95% CI)	3.05 [0.12, 75.20]
9 Endometrial hyperplasia	5	2846	Odds Ratio (M‐H, Random, 95% CI)	0.35 [0.05, 2.21]
9.1 Tibolone, 2.5 mg/day	5	1549	Odds Ratio (M‐H, Random, 95% CI)	0.35 [0.04, 3.36]
9.2 Tibolone, 1.25 mg/day	1	1297	Odds Ratio (M‐H, Random, 95% CI)	0.34 [0.01, 8.48]
10 Vaginal dryness and painful sexual intercourse	7	1098	Std. Mean Difference (Fixed, 95% CI)	0.02 [‐0.12, 0.17]
10.1 Tibolone, 2.5 mg/day	7	1098	Std. Mean Difference (Fixed, 95% CI)	0.02 [‐0.12, 0.17]
11 Sensitivity Analysis ‐ Vasomotor symptoms without trials with high risk of attrition bias	4		Std. Mean Difference (Fixed, 95% CI)	0.25 [0.09, 0.41]
12 Sensitivity analysis ‐ vasomotor symptoms ‐ excluding studies with attrition bias and using nonvalidated scales	3		Std. Mean Difference (Fixed, 95% CI)	‐0.03 [‐0.30, 0.23]
13 Vasomotor symptoms ‐ ordered by duration	9		Std. Mean Difference (Fixed, 95% CI)	0.17 [0.06, 0.28]
13.1 Tibolone, 2.5 mg/day	9		Std. Mean Difference (Fixed, 95% CI)	0.17 [0.06, 0.28]